Dose delivery characteristics and lung deposition of indacaterol/glycopyrronium/mometasone furoate (IND/GLY/MF) and IND/MF via Breezhaler device: An Alberta Idealised Throat (AIT) evaluation
J. Jauernig (Basel, Switzerland), K. Fiebich (Basel, Switzerland), D. Singh (Basel, Switzerland), X. Jaumont (Basel, Switzerland), K. Mezzi (Basel, Switzerland), X. Jaumont (La Madeleine, France)
Source: International Congress 2022 – Chronic airway diseases and infections: management and prevalence
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Jauernig (Basel, Switzerland), K. Fiebich (Basel, Switzerland), D. Singh (Basel, Switzerland), X. Jaumont (Basel, Switzerland), K. Mezzi (Basel, Switzerland), X. Jaumont (La Madeleine, France). Dose delivery characteristics and lung deposition of indacaterol/glycopyrronium/mometasone furoate (IND/GLY/MF) and IND/MF via Breezhaler device: An Alberta Idealised Throat (AIT) evaluation. 2414
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|